Log in
Enquire now
Egle Therapeutics

Egle Therapeutics

Biotherapies developer targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases.

OverviewStructured DataIssuesContributors

Contents

egle-tx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Healthcare
Healthcare
Oncology
Oncology
Immunotherapy
Immunotherapy
Technology
Technology
Cancer
Cancer
Biology
Biology
Biotechnology
Biotechnology
...
Location
France
France
Paris
Paris
0
B2X
B2B
B2B
CEO
‌
Christophe Queva
‌
Luc Boblet
0
Founder
‌
Luc Boblet
0
Pitchbook URL
pitchbook.com/profiles...439329-25
Number of Employees (Ranges)
11 – 50
Email Address
job@egle-tx.com
contact@egle-tx.com0
Phone Number
+331866408570
Full Address
Pépinière Cochin Paris Santé 29 Rue du Faubourg St Jacques 75014 Paris, France0
Investors
‌
Bioqube Ventures
0
Fund+
Fund+
0
Takeda Ventures
Takeda Ventures
0
Bpifrance
Bpifrance
0
‌
France 2030
EQT Life Sciences
EQT Life Sciences
0
Founded Date
January 1, 2020
Total Funding Amount (USD)
96,000,000
Latest Funding Round Date
March 17, 2025
CTO
‌
Reno Winter
Latest Funding Type
Series A
Series A
Country
France
France
0
Headquarters
Paris
Paris

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
10,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Egle Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.